



(11) **EP 3 207 931 A3**

(12) **EUROPEAN PATENT APPLICATION**

(88) Date of publication A3:
20.12.2017 Bulletin 2017/51

(51) Int Cl.:
A61K 31/685 ^(2006.01) **A61K 31/683** ^(2006.01)
A61K 31/661 ^(2006.01) **A61K 9/127** ^(2006.01)
A61P 9/00 ^(2006.01) **A61P 9/06** ^(2006.01)

(43) Date of publication A2:
23.08.2017 Bulletin 2017/34

(21) Application number: **16206296.2**

(22) Date of filing: **03.06.2015**

(84) Designated Contracting States:
AL AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HR HU IE IS IT LI LT LU LV MC MK MT NL NO PL PT RO RS SE SI SK SM TR
Designated Extension States:
BA ME
Designated Validation States:
MA

(30) Priority: **03.06.2014 US 201462007244 P**
09.08.2014 US 201462035417 P
29.09.2014 US 201462056957 P
20.04.2015 US 201562150059 P

(62) Document number(s) of the earlier application(s) in accordance with Art. 76 EPC:
15803421.5 / 3 151 837

(71) Applicants:
• **Signpath Pharma Inc.**
Quakertown, PA 18951 (US)

• **Avanti Polar Lipids Inc.**
Alabaster, Alabama 35007 (US)

(72) Inventors:
• **HELSON, Lawrence**
Quakertown, PA Pennsylvania 18951 (US)
• **SHOPP, George M.**
Boulder, CO Colorado 80302 (US)
• **BOUCHARD, Annie**
Stoke, Québec J0B 3G0 (CA)
• **MAJEED, Muhammed**
East Windsor, NJ New Jersey 08520 (US)
• **BURGESS, Stephen**
Chelsea, AL Alabama 35043 (US)
• **SHAW, Walter A.**
Birmingham, AL Alabama 35243 (US)

(74) Representative: **Sonn & Partner Patentanwälte**
Riemergasse 14
1010 Wien (AT)

(54) **PROTECTIVE EFFECT OF DMPC, DMPG, DMPC/DMPG, EGPG, LYSOPG AND LYSOPC AGAINST DRUGS THAT CAUSE CHANNELOPATHIES**

(57) The present invention includes compositions and methods for preventing one or more cardiac channelopathies or conditions resulting from irregularities or alterations in cardiac patterns caused by an active agent or a drug in a human or animal subject comprising: an amount of a lysophosphatidyl compound adapted for oral

administration effective to reduce or prevent one or more cardiac channelopathies or conditions resulting from irregularities or alterations in cardiac patterns caused by the active agent or drug. Such compositions may further comprise a monoglyceride, a free fatty acid or a combination of the foregoing, including, e.g., a eutectic mixture.

EP 3 207 931 A3



EUROPEAN SEARCH REPORT

Application Number
EP 16 20 6296

5

10

15

20

25

30

35

40

45

50

55

DOCUMENTS CONSIDERED TO BE RELEVANT			
Category	Citation of document with indication, where appropriate, of relevant passages	Relevant to claim	CLASSIFICATION OF THE APPLICATION (IPC)
X	WO 2012/167212 A2 (SIGNPATH PHARMA INC [US]; HELSON LAWRENCE [US]) 6 December 2012 (2012-12-06) * the whole document * * page 1, line 2 - line 4 * * page 1, line 10 - line 17 * * page 2, line 3 - line 15 * * page 3, line 14 - line 27 * * page 5, line 9 - line 12 * * claims 1-4,10 * -----	1-5	INV. A61K31/685 A61K31/683 A61K31/661 A61K9/127 A61P9/00 A61P9/06
E	WO 2015/095576 A1 (SIGNPATH PHARMA INC [US]) 25 June 2015 (2015-06-25) * page 3, line 30 - page 4, line 36 * * page 4, line 22 - line 35 * * page 5, line 27 - page 6, line 2 * * page 30, line 19 - line 22 * * page 45, line 17 - line 30 * * claims 1-25 * * claims 11-12,23-24 * -----	1-5	TECHNICAL FIELDS SEARCHED (IPC) A61K
The present search report has been drawn up for all claims			
Place of search Munich		Date of completion of the search 3 November 2017	Examiner Economou, Dimitrios
CATEGORY OF CITED DOCUMENTS X : particularly relevant if taken alone Y : particularly relevant if combined with another document of the same category A : technological background O : non-written disclosure P : intermediate document		T : theory or principle underlying the invention E : earlier patent document, but published on, or after the filing date D : document cited in the application L : document cited for other reasons & : member of the same patent family, corresponding document	

EPO FORM 1503 03/02 (P04C01)

ANNEX TO THE EUROPEAN SEARCH REPORT
ON EUROPEAN PATENT APPLICATION NO.

EP 16 20 6296

5 This annex lists the patent family members relating to the patent documents cited in the above-mentioned European search report.
The members are as contained in the European Patent Office EDP file on
The European Patent Office is in no way liable for these particulars which are merely given for the purpose of information.

03-11-2017

Patent document cited in search report	Publication date	Patent family member(s)	Publication date
WO 2012167212 A2	06-12-2012	CA 2836904 A1	06-12-2012
		EP 2714011 A2	09-04-2014
		GB 2507884 A	14-05-2014
		US 2012308643 A1	06-12-2012
		US 2014242156 A1	28-08-2014
		US 2016193149 A1	07-07-2016
		US 2017246110 A1	31-08-2017
		WO 2012167212 A2	06-12-2012

WO 2015095576 A1	25-06-2015	CA 2933204 A1	25-06-2015
		EP 3082768 A1	26-10-2016
		JP 2016540781 A	28-12-2016
		US 2015164878 A1	18-06-2015
		WO 2015095576 A1	25-06-2015
